All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.
Introducing
Now you can personalise
your MDS Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MDS Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MDS Hub cannot guarantee the accuracy of translated content. The MDS Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the MDS Hub was happy to speak to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked: What are the challenges in assessing response to treatment in MDS?
What are the challenges in assessing response to treatment in MDS?
Treatment assessment in patients with low-risk MDS is particularly challenging. Here, Uwe Platzbecker highlights the need for uniform assessment approaches in MDS.
Subscribe to get the best content related to MDS delivered to your inbox